New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Dogwood Therapeutics, Inc.

Contributing Author

Recent Articles by Dogwood Therapeutics, Inc.

Feb-02	Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron Phase 2b Trial, Top Line Results Anticipated in Q3 2026 DWTX +5.02% GlobeNewswire
Jan-12	Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development DWTX +5.61% GlobeNewswire
Dec-22	Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain DWTX -24.96% GlobeNewswire
Nov-06	Dogwood Therapeutics Reports Third Quarter 2025 Financial Results DWTX -6.47% GlobeNewswire
Sep-29	Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients DWTX +43.30% GlobeNewswire
Sep-03	Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference DWTX GlobeNewswire
Aug-13	Dogwood Therapeutics Reports Second Quarter 2025 Financial Results DWTX GlobeNewswire
Aug-07	Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron Phase 2b Trial DWTX GlobeNewswire
Aug-06	Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025 DWTX GlobeNewswire
Jun-03	Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference DWTX +6.26% GlobeNewswire
May-08	Dogwood Therapeutics Announces First Quarter 2025 Financial Results DWTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.